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Abstract

Erectile dysfunction (ED) is the inability to achieve and maintain an erection
sufficient for satisfactory sexual intercourse. It is the most frequent sexual dysfunction in
elderly men and its prevalence increases with age.
Ever since ED was recognized as a real health problem, several treatment options
became available and some of them proved to be very efficient. PDE5 inhibitors are the
mainstay treatment of ED.
However, other treatment options such as intracorporal injections, surgery, vacuum
devices and prosthesis are also available for patients who are unresponsive to PDE5
inhibitors. Since none of the treatment options available so far has proven ideal, research in
the field of sexual medicine continues. The aim of this paper is to review the most advances
in the treatment of ED.
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Introduction

vasodilatation and smooth muscle relaxation. As the

Erectile dysfunction (ED) is the inability to blood fills the sinusoids, intracorporal pressure
achieve and maintain an erection sufficient for increases

and

the

subtunical

venules

are

satisfactory sexual intercourse. It is the most compressed. The blood is trapped in the corpora
frequent sexual dysfunction in elderly men and its cavernosa and the penis becomes erect (5-7).
prevalence increases with age. It has a worldwide

The most important risk factors for ED are

occurrence. Studies show that approximately 52% aging, arterial hypertension, diabetes mellitus,
of men aged 40-70 years old are affected to some atherosclerosis,

hypercholesterolemia,

smoking,

degree by this disorder. While in young males, prostatectomy, and drugs.
under the age of 40 years, ED was initially
considered psychogenic, recent studies showed that Discussion
in 14.8% of the cases the ED is organic (1-3). ED

Classification of ED

has a great impact on the patient's and his partner's
ED can be classified as psychogenic, organic

quality of life as it can cause depression and anxiety
and it can decrease emotional intimacy and

and mixed. Organic ED can be further classified as
neurogenic, hormonal, vasculogenic, drug induced

satisfaction within a relationship (4).

or related to systemic diseases. Mixed ED is the

Penile erection is a complex neurovascular most common form of ED (6, 8).
process which involves neurological, molecular,
Psychogenic ED occurs more frequently in
vascular, endocrine and psychological factors.
Visual, olfactory and imaginary stimuli are also
important.

Sexual

arousal

releases

neuro-

transmitters, especially nitric oxide (NO), from
nonadrenergic-noncholinergic

cavernous

nerve

young men, under the age of 40 years. It can be
associated with depression, performance anxiety,
decreased

self-esteem,

schizophrenia/

stress

psychosis,

in

lack

relationship,
of

sexual

terminals, through the action of NO-synthetize. NO arousability, and fear or shame of venereal or
activates guanylate cyclase which converts dermatological diseases. Compared to organic ED,
guanosine

triphosphate

monophosphate

which

to

cyclic

guanosine psychogenic ED has a sudden onset, occurs in

phosphorylates

certain patients with psychological disorders or going

proteins and calcium channels, thus leading to through major life events, while spontaneous and
inhibition

of

calcium

channels,

decrease

in self-stimulated erections are of good quality (6, 8,

cytosolic calcium content and, in the end, 9).
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Neurogenic ED is responsible for 10-19% of venous leakage. Subclinical perineal trauma is also
ED cases. Several neurogenic disorders have been associated with ED and is probably determined by
associated with ED. Some patients with spinal cord the occurrence of focal arterial occlusive disease.
injuries or perineal trauma do not respond to genital That is also the case in young men who bicycle
stroke, Parkinson's more than 3 hours a week (3, 6, 11).

stimulation. Patients with

disease and Alzheimer's disease have decreased
libido and are not able to initiate the erectile

ED can be induced by several drugs through
various mechanisms. Antihypertensives like beta-

process. ED is up to three times more frequent in adrenergic blocking agents and thiazide diuretics,
patients with epilepsy. Multiple sclerosis is one of antiandrogens

like

the most prevalent neurologic disorders occurring in antidepressants

like

finasteride,
selective

NSAIDs,

serotonin

anti-

young men and in 70% of cases it is associated with reuptake inhibitors, anxiolytics and neuroleptics are
ED (3, 6, 10).

some of the medications most frequently associated

Several hormones and endocrine disorders
have been associated with ED. Klinefelter's
syndrome,

congenital

and

with ED (3).
Systemic diseases like diabetes mellitus,

acquired chronic renal failure, multiple sclerosis, and

hypogonadotropic hypogonadism are associated generalized atherosclerotic disease can often lead to
with androgen deficiency and decreased libido. ED (6).
Hyperprolactinemia

results

in

secondary

Erectile dysfunction treatment

hypogonadotropic hypogonadism and ED. Patients
with hyperthyroidism and hypothyroidism also have

Ever since ED was recognized as a real health
problem,

decreased erectile function (3, 6).

several

treatment

options

became

available and some of them proved very efficient.
Vascular

disorders

are

also

frequently

Lifestyle modifications, oral phosphodiesterase-5

responsible for ED. Adequate arterial inflow and (PDE5) inhibitors, intracorporal injections, topical
venous outflow occlusion are both mandatory in medication,
order to

surgery,

vacuum

devices,

and

achieve an erection. Hypertension, acupuncture are only some of the treatments

atherosclerosis, diabetes mellitus and trauma are available today for ED. However, since all these
associated with inadequate arterial inflow while treatments have limitations, the search for novel
veno-occlusive dysfunction is associated with therapies continues (12, 13).
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Phosphodiesterase inhibitors (PDE)

Lifestyle modifications
Since ED and coronary artery disease share

PDE inhibitors are the first-line treatment in

similar risk factors, it is easy to presume that the patients with ED. Studies show that all PDE
same lifestyle modifications required for cardiac inhibitors are safe and effective, especially in men
disease should be required for ED. According to the suffering from diabetes, multiple sclerosis,
cardiovascular disease and spinal cord injury. PDE5
European Association of Urology guidelines,
is specific for to cGMP. It has an abundant
lifestyle changes and risk factor management must
expression in corpus cavernosum and determines
precede or accompany any pharmacological
degradation of cGMP. Inhibition of PDE5 leads to
treatment, patients with cardiac disease and diabetes
high levels of cGMP, muscle relaxation and, in the
mellitus having the greatest benefits from these
end, erection (18).
changes (14, 15). Therefore, smoking cessation,
weight loss, physical activity, avoiding stress and

Sildenafil

was

the

first

PDE

inhibitor

the use of alcohol and illicit drugs should be successfully used for the treatment of ED. Even
though it is a selective PDE5 inhibitor, it crossrecommended to all patients suffering from ED (4).
reacts slightly with PDE6, which is mainly found in
Gupta et. al performed a systematic review
the retina. For that reason, some patients may
and meta-analysis of controlled trials assessing the
experience visual disturbances like altered color
effect of lifestyle changes and pharmacotherapy on perception and "star vision". The onset of action is
ED. They included 740 participants from 4 30 minutes after the first dose and the half-life is 3countries and concluded that pharmacotherapy for 5 hours. Studies show that 69% of patients taking
cardiovascular

risk

factors

and

lifestyle sildenafil will obtain an erection suitable for sexual

modifications are effective in patients with ED (16). intercourse, as compared to only 22% of patients
Some authors suggest that administration of
over the counter dietary supplements such as Panax

taking placebo (12, 18, 19).
Vardenafil is a fast-acting selective PDE5-

ginseng may be beneficial to patients with ED, it is inhibitor used for the treatment of ED. It has been
associated with low toxicity and low costs and, with used successfully in some patients who failed to
a physician’s knowledge, could be included in ED respond to sildenafil. It has an onset of action of 10
treatment (17).

minutes and an average half-life of 4.2 hours.
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Caution is advised in patients with prolonged QTc

Avanafil was approved by the FDA in 2012. It

who are taking class 1 and class 3 antiarrhythmics is a potent competitive inhibitor of PDE5. It is a
pyrimidine derivative which is rapidly absorbed and

(12, 18, 19).
„Revitalise”

it reaches the maximum concentration in 30-45
was

an

international
minutes (12, 18, 19). Cui et al. performed in 2014 a

observational study which included 1832 patients
systematic review and meta-analysis in which they
with ED and metabolic syndrome from 10 countries
included 1381 patients from randomized controlled
who were treated with vardenafil. The aim of the
studies which compared avanafil with placebo. The
study was to investigate the effectiveness and safety
authors concluded that patients treated with avanafil
of vardenafil in the clinical setting. The authors
100 mg were more likely to achieve successful
report that 82.4% of the patients had an increase of
vaginal penetration and successful intercourse. The
at least 4 points in the IIEF-EF score and that after
rate of discontinuation due to adverse events was
treatment 45.4% had normal erectile function. The
similar in the two groups. Avanafil 100 mg seems
authors therefore conclude that vardenafil is a good
to be as effective as avanafil 200 mg. The two
treatment option for patients with ED and metabolic
concentrations seem to have similar safety profiles
syndrome (20).
but headaches are more frequent in patients taking
Tadalafil is a selective PDE5 inhibitor which 200 mg of avanafil (22).
showed no cross-reactivity with PDE6 but some
cross-reactivity with PDE11. It is a safe drug which
proved its effectiveness in ED occurring in both
elderly and young men. It has an onset of 20
minutes and the longest duration of action for this
class of pro-erectile agents (up to 36 hours). It can

Udenafil

is

a

PDE5

specific

inhibitor

developed in Korea for the treatment of ED. It also
inhibits cGMP hydrolysis. It reaches peak plasma
concentrations in 0.8-1.3 hours and is associated
with rapid onset and a long duration. It is a well-

be administered on demand or administered daily, tolerated, safe, effective treatment for ED. It also
in small doses. Studies showed that 81% of patients proved its efficacy in patients with ED associated
treated with tadalafil were able to obtain an with diabetes mellitus, hypertension and lower
improvement in the erection quality, as compared to urinary tract symptoms. It can be administered on
35% of patients in the placebo arm (12, 18, 19, 21).

demand or daily (12, 23).
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Mirodenafil

is

another

selective

PDE5 weeks. As an alternative, testosterone patches and

inhibitor developed in Korea for the treatment of gels are available for daily use (27).
ED. Its selectivity for PDE5 is 10 fold higher that Alprostadil
sildenafil's selectivity for PDE5. It reaches the peak
Alprostadil is a synthetic prostaglandin E1
concentrations after 1.25 hours and it has a half-life
which has been approved for the treatment of ED.
of 2.5 hours. It has beneficial effects in patients
with ED and lower urinary tract symptoms and
benign prostatic hyperplasia. Daily treatment with
mirodenafil and on demand treatment are both
effective in patients with ED (12, 24).

Intracavernous alprostadil injections are a second
line treatment in ED. A study performed on 848
men

aged

18-75

intracavernosal

years

alprostadil

old

treated

showed

with

that

the

treatment is effective in achieving satisfactory
erections and safe (28). Fear of penile puncture and

Testosterone replacement therapy (TRT)

pain restrict the use of alprostadil injections.
In the past, testosterone was believed to
enhance sexual function in males. Currently,
however, it has been shown that testosterone is only
useful in males with hypogonadism. Hypogonadism

Alprostadil urethral suppositories are also a
second line treatment in ED. They have the
advantage of minimal adverse reaction and drug
interactions but their efficacy is lower than that of

usually affects older males and ED is one of its
symptoms. Even though TRT has beneficial effects
on

several

of

the

symptoms

related

controversial.

Some

studies

suggest

due to moderate to severe penile pain (6, 29, 30).

to

hypogonadism, data regarding its usefulness in ED
is

alprostadil injections and patient compliance is low

that

combining TRT with PDE5 inhibitors could be

Alprostadil cream is an alternative to urethral
suppositories

and

injections.

Rooney

et.

al

performed a study in 2009 in which they aimed to
evaluate the efficacy and safety of topical

helpful in patients who are unresponsive to PDE5
alprostadil. The study included 1161 patients with
inhibitors alone. Randomized controlled studies are
however necessary to support these observations
(25, 26).
Testosterone

ED who were asked to administer 200 mcg to the
penis meatus before intercourse for four weeks.
After four weeks the patients were asked to apply

cypionate

is

available

for 300 mcg if hypo-responsive and 100 mcg if hyper-

intramuscular injections administered every three responsive. The authors concluded that alprostadil
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cream was effective and safe for the patients and combination they act synergistically and are
their partners and the most frequent adverse events associated with a response rate of up to 90%. The
were limited to the application site (31).

most frequent and effective combination includes
papaverine, phentolamine and alprostadil (6, 12).

Other intracavernosal injections
Apart from aprostadil, other substances can

Stem cells

also be injected intracavernosally in patients who

Stem cells (SC) are intensely studied at

do not respond to oral treatment with PDE5 present, especially for the treatment of neurogenic
inhibitors.

ED where available therapies are not very effective.

Papaverine has multiple mechanisms of action
which make it useful in ED. It is a non-specific
PDE5 inhibitor; it decreases resistance to arterial
inflow and increases resistance to venous outflow.

SC can differentiate into endothelial cell, neurons,
smooth muscle cells and Schwann cells, among
others, and there is hope that once transplanted they
might help the regeneration of the injured tissue.

Its utilization is however limited by its side effects:
corporal fibrosis and priapism (6, 12).

adipose tissue-derived SC (ADSC), muscle-derived

Phentolamine is a competitive α-adrenoceptor
antagonist which can also determine histamine
release from mast cells. It can decrease resistance to
arterial

flow.

It

is

not

very

Three types of SC are generally used in ED:

effective

in

SC

The vasoactive intestinal peptide (VIP) is a
vasodilator that stimulates cAMP formation. It
failed to prove its efficacy in ED when administered
in monotherapy but showed some good results
when it was administered with phentolamine (12).
While the efficacy of this class of agents in

and

bone-marrow

derived

SC

(BMSC). The SC can be delivered by intravenous
injection, intracorporal injection or intraperitoneal
injection.

monotherapy. It can cause hypotension and reflex
tachycardia (6, 12).

(MDSC)

Studies involving SC were performed on
animal models, especially rats, and have shown
promising results. Since stem cells might provide a
cure for ED and not only symptom relief, the results
of

clinical

trials

on

men

with

ED

are

enthusiastically awaited (13, 32, 33).
Vacuum erection devices (VED)
Even though VED can be used for the

monotherapy is not very high, when used in treatment of ED of any etiology and have been
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recommended

by

the

Urological Surgical management

American

Association as an alternative therapy since 1998,

Surgical treatment is rarely necessary in

they only became more frequently used in the last patients with ED and it is reserved for patients who
years, especially in patients requiring penile are resistant to PDE5 inhibitors.
rehabilitation after radical prostatectomy.
Arterial revascularization has been tried in
VED produce negative pressure with the help patients with penile artery insufficiency of various
of a vacuum pump. This causes the distension of the causes but it mostly benefits young men with
corporal sinusoids and arterial blood inflow. A traumatic disruption of the vasculature. Several
constriction ring is placed at the base of the penis to
decrease venous outflow. As a result, the penis

technics are available but most commonly the
epigastric artery is anastomosed to the dorsal penile
artery. The revascularization technique is only

becomes erect. In patients with ED due to radical

effective in 30-50% of cases (6).

prostatectomy, VED help the recovery of erectile
function through anti-hypoxic, anti-apoptosis and

More recently, endovascular treatments were
tried in patients with vasculogenic ED refractory to

anti-fibrotic mechanisms. Some authors suggest that
PDE5 inhibitors. The Zen Trial (Zotarolimuswhen VED are used for penile rehabilitation, the
rubber ring should not be used, as it may lead to

Eluting Peripheral Stent System for the Treatment
of ED in Males with Sub-Optimal Response to

fibrosis as a result of prolonged ischemia and PDE5 Inhibitors) published in 2012 investigated the
acidosis.

use of drug-eluting stents in patients with focal

Studies show that VED are effective in up to
90% of patients. They allow sexual intercourse soon
after surgery and result in early return of natural

atherosclerotic lesions of the internal pudendal
artery. The drug they used was zotarolimus, an
immunosuppressive agent which prevents restenosis
and the rate of neointimalization. Even though the

erections.

authors obtained some promising results, larger

VED are non-invasive treatment methods and studies are necessary to support the usefulness of
the most commonly reported adverse reactions are the technique (11, 37, 38).
bruising, pain, cold penis or penile discomfort.
Caution

is

required

in

patients

anticoagulant treatment (10, 34-37).

Venous surgery should only be performed in

undergoing patients with proven venous leakage who have a
normal arterial response on duplex Doppler and
125
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who do not have generalized penile venous disease.

The long-term satisfaction rate is very high in

Surgical ligation of the deep dorsal vein and its patients

using

inflatable

and

non-inflatable

collaterals was used in the past but only showed prostheses. This procedure however is only
positive results in approximately 25% of patients (6, recommended to select patients who are willing to
11).

undergo implantation of a penile prosthesis (6, 40In 2013 Aschenbach et. al performed a study 42).

on 29 patients with ED due to veno-occlusive Other treatment options
dysfunction who were treated with endovascular
embolization therapy with N-butyl-2-cyanoacrylate.
The

procedure

was

performed

under

local

anesthesia, it was minimally invasive and clinical
success was achieved in 88,8% of the patients (39).

Several devices have been produced in the last
years for the treatment of ED. External support
devices such as penile casts, vibrators, low intensity
extracorporeal shockwave, impulse magnetic field
therapy or tissue engineering are just some of the

Prosthetic surgery is the third-line treatment in novel devices and procedures proposed for the
patients with ED and is only recommended in
patients

who

have

failed

or

refused

other

treatment of ED. Further studies are necessary to
prove the efficacy of those devices and procedures.
However, there are high hopes that some of them

treatments. Patients must be aware that prosthesis

might complete the therapeutic arsenal of ED (37).

surgery is irreversible and physiologic erections
will not be possible any more. Two types of Conclusions
prostheses

are

available:

non-inflatable

and

ED is a frequent sexual dysfunction which

inflatable. Non inflatable prostheses have the affects men worldwide and has a great impact on
advantage of being more durable and cheaper and the patient's and his partner's quality of life. PDE5
inhibitors are the mainstay treatment of ED. Several
the disadvantages of causing permanent erection,
other treatment options such as intracorporal
and they are difficult to conceal and device erosion
injections, surgery, vacuum devices and prosthesis
can occur. Inflatable prostheses have the advantage
are however available for patients who are
that they offer a flaccid state and an erect state and unresponsive to PDE5 inhibitors. Since none of the
the disadvantage that mechanical failure can occur. treatment options available so far proved ideal,
Infections are the most important adverse reactions.

research in the field of sexual medicine continues.
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